Menactra Launches For 11, 12, 15 Year Olds; First In Wave Of Teen Vaccines?
Executive Summary
Sanofi-Pasteur will have approximately 5 mil. doses of Menactra (meningococcal quadrivalent conjugate vaccine) available for use in the U.S. during the first 12 months following launch
You may also be interested in...
Menactra Returns To Normal Schedule; FluMist Seeks CDC Contract
FluMist CDC contract: MedImmune is negotiating a contract with the Centers for Disease Control & Prevention to supply its intranasal flu vaccine FluMist for the 2006-2007 season, VP & General Manager Mark Twyman says during a Oct. 25-26 meeting of CDC's Advisory Committee on Immunization Practices in Atlanta. The firm could supply the entire pediatric market by the 2008-2009 season, he says. Firm plans to produce 3 mil. doses of FluMist for the U.S. market for the current season and expects to have production, filling and distribution capacity for 20 mil. to 30 mil. doses for 2008-2009. MedImmune hopes to launch its refrigerator-stable version, CAIV-T (cold adapted influenza vaccine, trivalent), by next season. The firm hopes the non-freezer version will boost sluggish uptake...
Menactra Returns To Normal Schedule; FluMist Seeks CDC Contract
FluMist CDC contract: MedImmune is negotiating a contract with the Centers for Disease Control & Prevention to supply its intranasal flu vaccine FluMist for the 2006-2007 season, VP & General Manager Mark Twyman says during a Oct. 25-26 meeting of CDC's Advisory Committee on Immunization Practices in Atlanta. The firm could supply the entire pediatric market by the 2008-2009 season, he says. Firm plans to produce 3 mil. doses of FluMist for the U.S. market for the current season and expects to have production, filling and distribution capacity for 20 mil. to 30 mil. doses for 2008-2009. MedImmune hopes to launch its refrigerator-stable version, CAIV-T (cold adapted influenza vaccine, trivalent), by next season. The firm hopes the non-freezer version will boost sluggish uptake...
HHS adolescent vaccination “hot buttons”
The HHS National Vaccines Advisory Committee's adolescent working group identifies three "hot button" issues concerning adolescent immunization: school mandates for vaccination, informed consent and use of non-traditional venues for adolescent immunization. The group hopes to publish a draft "defining the problems" in the upcoming months and put out a report within a year. A number of adolescent vaccines have been approved recently, including Merck's human papillomavirus vaccine Gardasil and Sanofi-Pasteur's meningococcal conjugate vaccine Menactra (1"The Pink Sheet" Feb. 28, 2005, p. 28)...